Christine Ring - Jun 10, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
General Counsel
Signature
/s/ Christine Ring
Stock symbol
NRIX
Transactions as of
Jun 10, 2021
Transactions value $
-$33,050
Form type
4
Date filed
6/11/2021, 04:11 PM
Previous filing
May 11, 2021
Next filing
Jul 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $2.23K +1.2K +149.07% $1.86* 2.01K Jun 10, 2021 Direct F1
transaction NRIX Common Stock Sale -$29.2K -1K -49.88% $29.18 1.01K Jun 10, 2021 Direct F1, F2
transaction NRIX Common Stock Sale -$6.1K -200 -19.9% $30.52 805 Jun 10, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -1.2K -1.05% $0.00 113K Jun 10, 2021 Common Stock 1.2K $1.86 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $28.77 and the highest price at which shares were sold was $29.47. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3 Represents the weighted average sale price. The lowest price at which shares were sold was $30.08 and the highest price at which shares were sold was $30.95.
F4 The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.